Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Merck
Cantor Fitzgerald
Accenture
Chinese Patent Office
US Department of Justice
Medtronic
McKesson
Federal Trade Commission

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,778,366

« Back to Dashboard

Which drugs does patent 8,778,366 protect, and when does it expire?

Patent 8,778,366 protects EPANED KIT and is included in one NDA.

This patent has three patent family members in three countries.
Summary for Patent: 8,778,366
Title:Enalapril compositions
Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
Inventor(s): Rajewski; Lian G. (Lawrence, KS), Rajewski; Roger A. (Lawrence, KS), Haslam; John L. (Lawrence, KS), Heppert; Kathleen (Lawrence, KS), Beckloff; Michael C. (Leawood, KS), Segrave; Frank (Dublin, OH), Mauro; Robert (Miller Place, NY), Colabuono; Peter (Las Vegas, NV)
Assignee: University of Kanasas (Lawrence, KS) Silvergate Pharmaceuticals, Inc. (Dublin, OH)
Application Number:13/914,452
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,778,366
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 8,778,366

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Silvergate Pharms EPANED KIT enalapril maleate FOR SOLUTION;ORAL 204308-001 Aug 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF HYPERTENSION ➤ Sign Up
Silvergate Pharms EPANED KIT enalapril maleate FOR SOLUTION;ORAL 204308-001 Aug 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATMENT OF HEART FAILURE ➤ Sign Up
Silvergate Pharms EPANED KIT enalapril maleate FOR SOLUTION;ORAL 204308-001 Aug 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION ➤ Sign Up
Silvergate Pharms EPANED KIT enalapril maleate FOR SOLUTION;ORAL 204308-001 Aug 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPERTENSION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,778,366

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,568,747 Enalapril compositions ➤ Sign Up
9,855,214 Enalapril compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Dow
Teva
Express Scripts
US Army
Johnson and Johnson
Medtronic
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.